General
Preferred name
OFLOXACIN
Synonyms
LEVOFLOXACIN ()
Ofloxacin (DL8280) ()
Hoe-280 ()
DL8280 ()
7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0^{5,13}]trideca-5(13),6,8,11-tetraene-11-carboxylic acid ()
Tarivid ()
J01MA01 ()
Ofloxacine ()
Exocin ()
Tarivid I.V. ()
Floxin Otic ()
DL-8280 ()
Ocuflox ()
Visiren ()
HOE 280 ()
Ofloxacino ()
NSC-727071 ()
NSC-758178 ()
Tarivid 400 ()
Floxin ()
Ofloxacin-d8 (hydrochloride) ()
P&D ID
PD001409
CAS
82419-36-1
2930288-81-4
Tags
available
drug
Approved by
FDA
First approval
1990
Drug indication
hearing loss
Bacterial infection
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ROE
Ofloxacin is mainly eliminated by renal excretion, where between 65% and 80% of an administered oral dose of ofloxacin is excreted unchanged via urine within 48 hours of dosing. About 4-8% of an ofloxacin dose is excreted in the feces and the drug is minimally subject to biliary excretion.
DESCRIPTION
Ofloxacin is a second generation fluoroquinolone antibacterial.
(GtoPdb)
PRICE
29
DESCRIPTION
Ofloxacin (Hoe-280) is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase. Ofloxacin shows inhibitory activity against vaccinia virus (VV).
DESCRIPTION
Ofloxacin (Oxaldin) is a fluoroquinolone antibacterial antibiotic. Ofloxacin binds to and inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, enzymes involved in DNA replication and repair, resulting in cell death in sensitive bacterial species.
DESCRIPTION
Fluorinated quinolone antibacterial; interferes with DNA synthesis
(LOPAC library)
DESCRIPTION
Ofloxacin is a broad spectrum fluoroquinolone antibiotic that prevents supercoiling of bacterial chromosomes by DNA gyrase. It is active against Gram-positive and Gram-negative bacteria
(Enamine Bioactive Compounds)
DESCRIPTION
Antibacterial activity against Enterobacter cloacae ATCC 13047; Inhibition of Escherichia coli DNA gyrase GyrA/GyrB assessed as concentration required for inducing cleavage
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
5
Compound Sets
26
AdooQ Bioactive Compound Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2023/24
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LOPAC library
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
57
Molecular Weight
361.14
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
4
Aromatic Ring Count
2
cLogP
1.54
TPSA
75.01
Fraction CSP3
0.44
Chiral centers
1.0
Largest ring
6.0
QED
0.87
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
DNA Synthesis
Target
antibiotic
Bacterial
Endogenous Metabolite
Orthopoxvirus
Topoisomerase
Therapeutic Class
Antibiotics
Pathway
Anti-infection
Metabolic Enzyme/Protease
Source data
